Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenQuadfi booster and immune persistence study in children and adolescents previously primed as toddlers
2023-510145-25-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, open-label trial of meningococcal A conjugate vaccine in meningococcal disease (3 arms), sponsored by Sanofi. Planned start Aug 2022; status: authorised.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2023-510145-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510145-25-00.